Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Agios (Nasdaq: AGIO) announced its management will present at the 44th Annual J.P.

Rhea-AI Summary

Agios (Nasdaq: AGIO) announced its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 8:15 a.m. PST / 11:15 a.m. EST. The presentation will be available via a live webcast on the company’s Investors site under “Events & Presentations.” A replay will be archived on the company website for at least two weeks after the presentation.

Argus Jan 5 session

+0.99% close to close Open Argus

Details

News Market Reaction – AGIO

On Jan 5, the day this news came out, AGIO closed 0.99% above the previous close.

Data tracked by StockTitan Argus for the Jan 5 session.

Market Context

This announcement highlights AGIO’s upcoming presentation at the high-profile J.P. Morgan Healthcare...

Analysis

This announcement highlights AGIO’s upcoming presentation at the high-profile J.P. Morgan Healthcare Conference on January 14, 2026, offering management another platform to discuss its rare disease portfolio and recent FDA approval of AQVESME™. With shares trading below the $34.19 200-day MA and about 40.91% under the $46 52-week high, investors may focus on any incremental clinical, commercial, or capital allocation commentary shared during the webcast and archived replay.

Key Figures

Conference date: January 14, 2026 Presentation time PST: 8:15 a.m. PST Presentation time EST: 11:15 a.m. EST +1 more

Conference date

January 14, 2026

Scheduled J.P. Morgan Healthcare Conference presentation

Presentation time PST

8:15 a.m. PST

Start time of conference presentation

Presentation time EST

11:15 a.m. EST

Start time of conference presentation

Webcast replay duration

at least two weeks

Duration replay will be archived on company website

Historical Context

5 past events · Latest: Dec 23

5 events

1. Dec 23

   FDA approval

   24h Move

   -1.4%

   U.S. FDA approval of AQVESME for anemia in alpha/beta-thalassemia.

2. Dec 08

   Regulatory update

   24h Move

   -1.6%

   FDA decision on mitapivat sNDA delayed, application remains under review.

3. Nov 19

   Clinical trial data

   24h Move

   -50.9%

   RISE UP Phase 3 hit hemoglobin endpoint but missed key secondary endpoints.

4. Nov 03

   Conference data

   24h Move

   -7.2%

   New mitapivat data in rare blood disorders at ASH 2025 meeting.

5. Oct 30

   Earnings update

   24h Move

   +2.9%

   Q3 2025 results with PYRUKYND revenue growth and strong cash balance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that its management team is scheduled to present at the 44^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 8:15 a.m. PST / 11:15 a.m. EST.

The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.

About Agios: Fueled by Connections to Transform Rare Diseases™
At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities – collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.

Contacts:

Investor Contact
Morgan Sanford, Vice President, Investor Relations
Agios Pharmaceuticals
morgan.sanford@agios.com

Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
eamonn.nolan@agios.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Agios (AGIO) present at the J.P. Morgan Healthcare Conference in 2026?

Agios will present on January 14, 2026 at 8:15 a.m. PST / 11:15 a.m. EST.

Where can investors watch the Agios (AGIO) live webcast for the January 14, 2026 presentation?

The live webcast will be available on Agios' Investors website under the Events & Presentations tab.

How long will the replay of the Agios (AGIO) J.P. Morgan presentation be available online?

A replay will be archived on the company website for at least two weeks following the presentation.

What time is Agios (AGIO) speaking in Eastern Time at the J.P. Morgan conference?

The presentation is scheduled for 11:15 a.m. EST on January 14, 2026.

Will Agios (AGIO) provide presentation materials or slides at the J.P. Morgan Healthcare Conference?

Presentation materials are typically posted under Events & Presentations on the Investors site; check the company website around the presentation time.

Can international investors access the Agios (AGIO) webcast for the January 14, 2026 presentation?

Yes, the live webcast is accessible via the company’s Investors website; replay will be available for at least two weeks afterward.